isotretinoin and Autoimmune-Diseases

isotretinoin has been researched along with Autoimmune-Diseases* in 3 studies

Reviews

1 review(s) available for isotretinoin and Autoimmune-Diseases

Article	Year
[Severe acne]. Annales de dermatologie et de venereologie, 2003, Volume: 130, Issue:1 Pt 2 Topics: Acne Vulgaris; Adrenal Cortex Hormones; Autoimmune Diseases; Humans; Inflammation; Isotretinoin; Prognosis; Severity of Illness Index	2003

Other Studies

2 other study(ies) available for isotretinoin and Autoimmune-Diseases

Article	Year
Ugeskrift for laeger, 2023, Jan-30, Volume: 185, Issue:5 A 36-year-old woman received isotretinoin treatment for acne and shortly after developed a silent thyroiditis. A 26-year-old woman likewise was treated with isotretinoin for acne and developed Graves' disease two and a half months after treatment. Both patients were without personal or familiar history of thyroid disease. These case reports describe two young women who in proximity to treatment with isotretinoin developed thyroid disease. We propose screening for development of thyroid disease as a part of the already established control regime for isotretinoin patients. Topics: Acne Vulgaris; Adult; Autoimmune Diseases; Female; Graves Disease; Humans; Isotretinoin	2023
The Effect of Isotretinoin on Vitiligo and Autoimmune Comorbidity. Journal of drugs in dermatology : JDD, 2020, Jun-01, Volume: 19, Issue:6 Several case reports have noted development of vitiligo as a potential side-effect of isotretinoin. In an IRB approved on-line survey of vitiligo patients we queried 1,301 vitiligo patients, 1115 with generalized vitiligo responding as to whether they had taken isotretinoin to address whether this issue was a common phenomenon amongst vitiligo patients. 3.6% of respondents had taken isotretinoin, 1.4% (n=16) before onset of vitiligo, and 2.2% (n=24) after onset of vitiligo. When compared with age-matched vitiligo peers who had not taken isotretinoin before onset of vitiligo (n=64) , isotretinoin use prior to onset of vitiligo was associated with: decreased disease body surface area (conditional logistic regression: OR of BSA≥50% (95% CI)=0.12 (0.03–0.57), P=0.007); decreased odds of body and face involvement when compared with either body or face alone (OR (95% CI)=0.20 (0.06–0.73), P=0.02); and decreased co-morbid autoimmunity (OR (95% CI)=0.17 (0.04–0.58), P=0.01). The volume of isotretinoin usage in vitiligo patients is additionally suggestive of a link between cystic acne and vitiligo. J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.4938. Topics: Adolescent; Adult; Autoimmune Diseases; Dermatologic Agents; Female; Humans; Incidence; Internet; Isotretinoin; Male; New York; Surveys and Questionnaires; Vitiligo; Young Adult	2020

Article

Year

Ugeskrift for laeger, 2023, Jan-30, Volume: 185, Issue:5

A 36-year-old woman received isotretinoin treatment for acne and shortly after developed a silent thyroiditis. A 26-year-old woman likewise was treated with isotretinoin for acne and developed Graves' disease two and a half months after treatment. Both patients were without personal or familiar history of thyroid disease. These case reports describe two young women who in proximity to treatment with isotretinoin developed thyroid disease. We propose screening for development of thyroid disease as a part of the already established control regime for isotretinoin patients.

Topics: Acne Vulgaris; Adult; Autoimmune Diseases; Female; Graves Disease; Humans; Isotretinoin

2023

The Effect of Isotretinoin on Vitiligo and Autoimmune Comorbidity.

Journal of drugs in dermatology : JDD, 2020, Jun-01, Volume: 19, Issue:6

Several case reports have noted development of vitiligo as a potential side-effect of isotretinoin. In an IRB approved on-line survey of vitiligo patients we queried 1,301 vitiligo patients, 1115 with generalized vitiligo responding as to whether they had taken isotretinoin to address whether this issue was a common phenomenon amongst vitiligo patients. 3.6% of respondents had taken isotretinoin, 1.4% (n=16) before onset of vitiligo, and 2.2% (n=24) after onset of vitiligo. When compared with age-matched vitiligo peers who had not taken isotretinoin before onset of vitiligo (n=64) , isotretinoin use prior to onset of vitiligo was associated with: decreased disease body surface area (conditional logistic regression: OR of BSA≥50% (95% CI)=0.12 (0.03–0.57), P=0.007); decreased odds of body and face involvement when compared with either body or face alone (OR (95% CI)=0.20 (0.06–0.73), P=0.02); and decreased co-morbid autoimmunity (OR (95% CI)=0.17 (0.04–0.58), P=0.01). The volume of isotretinoin usage in vitiligo patients is additionally suggestive of a link between cystic acne and vitiligo. J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.4938.

Topics: Adolescent; Adult; Autoimmune Diseases; Dermatologic Agents; Female; Humans; Incidence; Internet; Isotretinoin; Male; New York; Surveys and Questionnaires; Vitiligo; Young Adult

2020